24 Hour Crisis Hotline
800-336-0341
 
Know Your Rights
- Customer Service
- Recipient Rights
Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders

FDA Issues Maalox Total Relief Warning

HealthDay News
by -- Beth Gilbert
Updated: Feb 18th 2010

new article illustration

THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food and Drug Administration is warning consumers not to mistake Maalox Total Relief, a gastrointestinal and anti-diarrhea medication, for Maalox antacids (Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength), as this could result in serious side effects.

Maalox Total Relief is packaged and labeled similarly to Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength, which are available over the counter. The active ingredient in Maalox Total Relief, bismuth subsalicylate, is contraindicated in individuals with a history of gastrointestinal disease or bleeding disorder, and in those taking certain prescription medications such as blood thinners, anti-inflammatory drugs and oral antidiabetic drugs. In addition, adolescents and teens recovering from viral infections should not take Maalox Total Relief.

As of September, Novartis Consumer Health Inc., the manufacturers of these three products, will change the name of Maalox Total Relief, removing "Maalox" from the label and altering the packaging design. In addition to tracking any reported adverse reactions, the company will be launching an educational campaign, targeting both consumers and health care practitioners, to provide information regarding indications and safety of currently available Maalox products.

According to a Feb. 17 press release issued by the agency, "Maalox Total Relief and Maalox are not interchangeable and shouldn't be used in place of each other. Consumer confusion and incorrect product use due to name confusion are serious public health issues."

Press Release
More Information




Contact Riverwood Center 

By Mail
Riverwood Center
P.O. Box 547
Benton Harbor, MI 49023

By Email
info@riverwoodcenter.org

By Phone
Main: 269-925-0585
Niles: 269-684-4270

By Fax
269-927-6063


powered by centersite dot net